Global Sarcopenia Therapeutic Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Sarcopenia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Sarcopenia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Report Coverage Sarcopenia - Overview Sarcopenia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Sarcopenia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Sarcopenia - Companies Involved in Therapeutics Development Amgen Inc Biophytis SA Faraday Pharmaceuticals Inc GlaxoSmithKline Plc Immusoft Corp MYOS RENS Technology Inc Neurotune AG Novartis AG Regeneron Pharmaceuticals Inc ST Pharm Co., Ltd. Teijin Pharma Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bblbrc/global_sarcopenia?w=4.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006099/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Musculoskeletal Disorders Drugs,Drugs by Therapeutic Area
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 06:21 PM/DISC: 09/26/2018 06:21 PM